Erastin: Precision Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (SKU B1524) is a selective ferroptosis inducer that triggers iron-dependent, non-apoptotic cell death in tumor cells with RAS or BRAF mutations, making it a cornerstone tool in cancer biology research (APExBIO Product Page). Its mechanism involves inhibition of the cystine/glutamate antiporter system Xc⁻, leading to oxidative stress and lipid peroxidation (Zhang et al., 2023). Erastin's effects are distinct from caspase-dependent apoptosis, offering unique insights into redox regulation and therapy resistance. Experimental use is standardized at 10 μM for 24 hours in human tumor cell models. APExBIO supplies Erastin with validated quality for reproducible ferroptosis research.

Biological Rationale

Ferroptosis is a form of regulated cell death characterized by iron-dependent accumulation of lipid peroxides. Unlike apoptosis, it does not involve caspase activation or typical morphological features of apoptotic cells (Zhang et al., 2023). Tumor cells with RAS family (HRAS, KRAS) or BRAF mutations are particularly sensitive to ferroptosis due to altered redox homeostasis and increased reactive oxygen species (ROS) production. The cystine/glutamate antiporter system Xc⁻ imports cystine for glutathione synthesis, which is essential for mitigating oxidative damage. Inhibition of this system disrupts antioxidant defense and sensitizes cells to ferroptosis, a mechanism exploited by Erastin. The critical involvement of ferroptosis in cancer therapy resistance, especially in platinum-resistant ovarian and other solid tumors, underscores the need for robust tools to study this pathway (Zhang et al., 2023).

Mechanism of Action of Erastin

Erastin exerts its effect by binding to and modulating the voltage-dependent anion channel (VDAC) on the mitochondrial membrane and directly inhibiting system Xc⁻ (SLC7A11). This dual action blocks cystine import, depleting intracellular glutathione and impairing the activity of glutathione peroxidase 4 (GPX4). As a result, cells accumulate ROS and lipid peroxides, culminating in ferroptotic cell death rather than apoptosis or necrosis (Zhang et al., 2023). Erastin’s selectivity for tumor cells with activated RAS/RAF pathways is attributed to the heightened basal oxidative burden in these cells. Recent studies have also shown that ferroptosis sensitivity is modulated by lipid composition and antioxidant system efficiency, factors that can be experimentally manipulated using Erastin as a probe (Related Article). This article extends prior discussions by detailing the stepwise inhibition of system Xc⁻ and direct consequences for redox homeostasis.

Evidence & Benchmarks

• Erastin induces ferroptosis in RAS- or BRAF-mutant tumor cells at 10 μM for 24 hours, resulting in marked accumulation of lipid ROS and cell death (Zhang et al., 2023).
• Erastin-mediated inhibition of system Xc⁻ reduces intracellular glutathione (GSH) concentrations by >70% under standard culture conditions (Zhang et al., 2023).
• Ferroptosis triggered by Erastin is caspase-independent, as shown by the lack of effect of pan-caspase inhibitors on Erastin-induced cell death (Related Article).
• Erastin’s effects are abrogated by iron chelators (e.g., deferoxamine), confirming the iron-dependency of the cell death mechanism (Zhang et al., 2023).
• Engineered HT-1080 fibrosarcoma cells are a standard model for benchmarking Erastin-induced ferroptosis responses in vitro (Protocol Guide).

Applications, Limits & Misconceptions

Erastin is widely used for:

• Ferroptosis research: Modeling iron-dependent non-apoptotic cell death mechanisms.
• Cancer biology: Dissecting redox vulnerabilities of RAS/BRAF-mutant tumors and therapy resistance pathways.
• Oxidative stress assays: Quantitative assessment of ROS and antioxidant responses.

Compared to earlier reports, this article provides a more granular map of Erastin's mechanism, especially in relation to system Xc⁻ and VDAC. For broader translational perspectives, see "Erastin and the Translational Frontier," which focuses on clinical and biomarker contexts. This current article clarifies the experimental and molecular details relevant for laboratory investigators.

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis or necroptosis; its effect is caspase-independent (Zhang et al., 2023).
• Erastin's activity requires labile iron; iron chelators block its function.
• Water or ethanol are not suitable solvents for Erastin; only DMSO at ≥10.92 mg/mL with gentle warming ensures solubility (APExBIO).
• Long-term storage of Erastin solutions leads to degradation; always prepare fresh solutions for each experiment.
• Erastin is selective for cells with disrupted redox homeostasis (often RAS/BRAF-mutant); non-transformed cells may be less sensitive.

Workflow Integration & Parameters

For experimental use, Erastin should be dissolved in DMSO at concentrations ≥10.92 mg/mL with gentle warming. Recommended working concentration is 10 μM, incubated with engineered human tumor cells or HT-1080 fibrosarcoma cells for 24 hours at 37°C, 5% CO₂ (Protocol Guide). Store Erastin powder at -20°C. Avoid repeated freeze-thaw cycles. APExBIO’s Erastin (SKU B1524) is validated for these parameters (product page). For detailed mechanistic synergy with other pathway inhibitors and translational advice, see "Erastin and the Next Frontier"; this current dossier emphasizes core solubility and stability details for bench scientists.

Conclusion & Outlook

Erastin remains the reference ferroptosis inducer for dissecting iron-dependent, non-apoptotic cell death and modeling therapy resistance in oncology research. Its selective action on RAS/BRAF-mutant cell lines, robust mechanistic profile, and validated protocols (as provided by APExBIO) ensure reproducibility and scientific rigor. Ongoing studies are extending Erastin’s utility to biomarker discovery and combinatorial cancer therapy strategies. For further reading, the article "Erastin as a Ferroptosis Research Tool" offers integrative insights into Erastin’s role in prognostic model development, complementing the experimental focus presented here.